Table 2.

Characteristics of the HIV-Infected and HIV-Exposed But Uninfected Children at or Near the Time of Fracture

HIV status	Fracture location	Year of fracture	Sex	Age at fracture (years)	HTZ	WTZ	BMI z	Any NRTI	TDF	d4T	Any PI	CD4%	VL (copies/ml)
Infected	Femoral condyle	2001	M	6.1	−2.4	1.0	2.7	Yes	No	Yes	Yes	31	37,111
Infected	Leg	2003	F	7.1	1.1	2.1	2.0	Yes	No	No	Yes	32	212
Infected	Tibia	2006	M	5.9	−1.2	−0.8	0.1	Yes	No	Yes	Yes	21	42,100
Infected	Ankle	2006	M	11.6	1.2	1.6	1.5	Yes	No	Yes	No	33	75
Infected	Femur	2002	F	8.6	0.7	2.7	2.6	No	No	No	No	20	5,080
Infected	Ankle	2006	M	12.3	−0.7	−0.4	0.1	Yes	No	Yes	Yes	28	8,630
Infected	Wrist	2006	F	9.9	−1.5	−1.5	−0.8	Yes	No	Yes	No	35	1,480
HEU	Humerus	2006	F	6.2	2.6	2.3	1.6	—	—	—	—	—	—
HEU	Leg	2005	F	9.9	0.3	0.0	0.0	—	—	—	—	—	—

HEU, HIV exposed but uninfected. Fracture location, year of fracture, sex, and age were at the time of fracture. Height z (HTZ), weight z (WTZ), and BMI z reflect values obtained at the time of fracture or at the last 219/219C visit before the fracture. Exception is for HEU subject with 2005 leg fracture for whom values from the first 219/219C visit after the fracture were used, since values at the prefracture visit were missing. Antiretroviral therapy, CD4%, and viral load were at the visit prior to the fracture. NRTI, nucleoside analogue reverse transcriptase inhibitor; TDF, tenofovir disoproxil fumarate; D4T, stavudine; PI, protease inhibitor; CD4%, last CD4⁺ T-lymphocyte percentage; VL, viral load (copies/ml); M, male; F, female.